QCG
CALA

Quadrant Capital Group’s Calithera Biosciences, Inc CALA Stock Holding History

Quadrant Capital Group’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-43
Closed -$4K – 2116
2016
Q1 		$4K Buy
+43
New +$4.87K ﹤0.01% 1248

Other funds holding CALA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrant Capital Group's CALA Position: Q2 2016 in Review

Quadrant Capital Group sold out of Calithera Biosciences, Inc (CALA) in Q2 2016, closing a stake of 43 shares — an estimated $4K sold.

Quadrant Capital Group first reported a position in CALA in Q1 2016 and held it in 1 quarter. The position peaked at $4K in Q1 2016. 44 funds tracked by Wall St. Rank hold CALA as of Q2 2016.

  • Quadrant Capital Group reported no remaining Calithera Biosciences, Inc position as of Q2 2016 after selling out during the quarter.
  • Quadrant Capital Group sold 43 Calithera Biosciences, Inc shares in Q2 2016, an estimated $4K.
  • Quadrant Capital Group first reported a position in Calithera Biosciences, Inc in Q1 2016 and held it in 1 quarter.
  • Quadrant Capital Group's Calithera Biosciences, Inc position peaked at $4K in Q1 2016.
  • 44 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2016.

Based on Quadrant Capital Group's 13F filing for Q2 2016, filed 28 Jul 2016.